Single Daily Pill Shows Promise as Replacement for Complex HIV Treatment

A new, once-daily oral tablet combining bictegravir and lenacapavir (BIC/LEN) may offer a simpler treatment option for people living with HIV, particularly those who have been on long-term therapy, according to the results of a phase 3 clinical trial published in The Lancet.

Study Findings

The trial, involving over 550 participants across 15 countries, demonstrated that the BIC/LEN single-pill regimen was highly effective in maintaining viral suppression – defined as HIV virus levels below 50 copies/mL. Approximately 96% of participants who switched to the new treatment maintained viral suppression, with no new drug resistance emerging. This was comparable to the 94-96% viral suppression rate observed in participants who continued their existing, more complex multi-pill treatments.

Who Benefits from This New Treatment?

The study population had a median age of 60, significantly older than typical participants in HIV medication trials. Many participants had been managing their HIV with between two and eleven pills daily, with around 40% taking antiretrovirals more than once a day. A substantial portion also had pre-existing health conditions like cardiovascular or kidney disease, and most had previously developed resistance to HIV therapies.

Safety and Tolerability

Researchers found no significant or previously unknown safety concerns associated with the BIC/LEN combination. Notably, many participants experienced fewer lipid-related side effects, such as increased cholesterol levels, potentially offering an added benefit for those at risk of heart disease. Participants also reported the new treatment was easier and more convenient to capture, which can improve adherence to daily medication.

Looking Ahead

The study authors suggest this new option is particularly beneficial for older adults living with HIV, individuals with a history of drug resistance, or those managing multiple medications for HIV and other health conditions. Further clinical trials are underway to assess the long-term safety and effectiveness of the BIC/LEN combination. The findings were also presented at the Conference on Retroviruses and Opportunistic Infections (CROI) 2026 in Denver, Colorado.